Big pharma scores first victory in IPR battle with Bass and Spangenberg, but the war is far from over
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Editor
@IAM_magazine NPEs often give patent pools a wide berth but as Conversant CEO Boris Teksler claims joining a pool can help a lice… https://t.co/WhvPZ2ltRN Read more
@IAM_magazine Canon IP boss Kenichi Nagasawa explains how the Japanese company is adjusting its IP strategy to the 'new normal'… https://t.co/Wzg5W7fcvh Read more
@IAM_magazine Some interesting new numbers from @uspto Director Andrei Iancu who has revealed that maintenance fees for May-Augus… https://t.co/vEGxLJ5HHW Read more
@IAM_magazine RT @IP_IdeasMatter: It really is important to understand #intellectualproperty! @IAM_magazine Read more